ClinicalTrials.Veeva

Menu

Cytokine and Eicosanoid Mediators in Coronavirus Disease 2019 (COVID-19)

E

EicOsis

Status

Unknown

Conditions

COVID-19

Study type

Observational

Funder types

Industry

Identifiers

NCT04452942
EC1153-2-01

Details and patient eligibility

About

This study is a prospective, single center, observational, cohort study of patients to (1) describe the kinetics and temporal relationship of changes in eicosanoid and cytokine mediators in patients with severe COVID-19 admitted to the hospital; and (2) correlate the dynamic changes in eicosanoid mediators with available patient clinical status, including measures of severity of illness, routine laboratory tests, and outcomes.

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Admitted to a hospital with symptoms suggestive of COVID-19.
  2. Confirmed infection with SARS-CoV-2 as determined by polymerase chain reaction (PCR) or other commercial or public health assay in the 72 hours prior to hospital admission or any time during hospital admission.
  3. Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures.
  4. Understands and agrees to comply with planned study procedures.
  5. Agrees to the collection of whole blood samples.

Exclusion criteria

  1. Inability to obtain informed consent.
  2. Anticipated transfer to another hospital which is not a study site within 48 hours.
  3. Inability to obtain sequential blood samples due to patient's characteristics (i.e. difficult vascular access).
  4. Obstetric patients.
  5. Prisoners.

Trial contacts and locations

1

Loading...

Central trial contact

Irene Cortes-Puch, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems